• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MND1 和 PSMC3IP 控制有丝分裂细胞中 PARP 抑制剂的敏感性。

MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.

机构信息

The CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK; Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.

Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland; Departement of Biomedical Research (DBMR), Cancer Therapy Resistance Cluster, University of Bern, 3012 Bern, Switzerland.

出版信息

Cell Rep. 2023 May 30;42(5):112484. doi: 10.1016/j.celrep.2023.112484. Epub 2023 May 9.

DOI:10.1016/j.celrep.2023.112484
PMID:37163373
Abstract

The PSMC3IP-MND1 heterodimer promotes meiotic D loop formation before DNA strand exchange. In genome-scale CRISPR-Cas9 mutagenesis and interference screens in mitotic cells, depletion of PSMC3IP or MND1 causes sensitivity to poly (ADP-Ribose) polymerase inhibitors (PARPi) used in cancer treatment. PSMC3IP or MND1 depletion also causes ionizing radiation sensitivity. These effects are independent of PSMC3IP/MND1's role in mitotic alternative lengthening of telomeres. PSMC3IP- or MND1-depleted cells accumulate toxic RAD51 foci in response to DNA damage, show impaired homology-directed DNA repair, and become PARPi sensitive, even in cells lacking both BRCA1 and TP53BP1. Epistasis between PSMC3IP-MND1 and BRCA1/BRCA2 defects suggest that abrogated D loop formation is the cause of PARPi sensitivity. Wild-type PSMC3IP reverses PARPi sensitivity, whereas a PSMC3IP p.Glu201del mutant associated with D loop defects and ovarian dysgenesis does not. These observations suggest that meiotic proteins such as MND1 and PSMC3IP have a greater role in mitotic DNA repair.

摘要

PSMC3IP-MND1 异二聚体在 DNA 链交换前促进减数分裂 D 环形成。在有丝分裂细胞的全基因组规模的 CRISPR-Cas9 诱变和干扰筛选中,PSMC3IP 或 MND1 的耗竭导致对用于癌症治疗的聚(ADP-核糖)聚合酶抑制剂(PARPi)敏感。PSMC3IP 或 MND1 的耗竭也会导致电离辐射敏感。这些效应独立于 PSMC3IP/MND1 在有丝分裂端粒的替代性延长中的作用。PSMC3IP 或 MND1 耗竭的细胞在响应 DNA 损伤时积累有毒的 RAD51 焦点,显示同源定向 DNA 修复受损,并对 PARPi 敏感,即使在缺乏 BRCA1 和 TP53BP1 的细胞中也是如此。PSMC3IP-MND1 与 BRCA1/BRCA2 缺陷之间的上位性表明,D 环形成的中断是 PARPi 敏感性的原因。野生型 PSMC3IP 逆转了 PARPi 敏感性,而与 D 环缺陷和卵巢发育不良相关的 PSMC3IP p.Glu201del 突变体则没有。这些观察结果表明,减数分裂蛋白(如 MND1 和 PSMC3IP)在有丝分裂 DNA 修复中具有更大的作用。

相似文献

1
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.MND1 和 PSMC3IP 控制有丝分裂细胞中 PARP 抑制剂的敏感性。
Cell Rep. 2023 May 30;42(5):112484. doi: 10.1016/j.celrep.2023.112484. Epub 2023 May 9.
2
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.评估候选生物标志物以预测癌症细胞对 PARP-1 抑制剂治疗的敏感性或耐药性。
Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.
3
Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.早期有丝分裂抑制剂 1(EMI1)耗竭对 BRCA1 突变型三阴性乳腺癌细胞中 PARP 抑制剂敏感性的调节。
PLoS One. 2021 Jan 7;16(1):e0235025. doi: 10.1371/journal.pone.0235025. eCollection 2021.
4
XRCC8 mutation causes hypersensitivity to PARP inhibition without Homologous recombination repair deficiency.XRCC8 突变导致对 PARP 抑制的超敏反应,而没有同源重组修复缺陷。
Mutat Res. 2023 Jan-Jun;826:111815. doi: 10.1016/j.mrfmmm.2023.111815. Epub 2023 Feb 13.
5
Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.PARP 抑制剂与电离辐射的合成致死性依赖于 p53。
Mol Cancer Res. 2018 Jul;16(7):1092-1102. doi: 10.1158/1541-7786.MCR-18-0106. Epub 2018 Mar 28.
6
Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.表观遗传诱导的BRCAness后关键DNA损伤修复基因表达的差异决定了PARP1抑制后的合成致死性。
Mol Cancer Ther. 2015 Oct;14(10):2321-31. doi: 10.1158/1535-7163.MCT-15-0374. Epub 2015 Aug 20.
7
FANCM promotes PARP inhibitor resistance by minimizing ssDNA gap formation and counteracting resection inhibition.FANCM 通过最小化单链 DNA 缺口的形成和拮抗切除抑制来促进 PARP 抑制剂耐药性。
Cell Rep. 2024 Jul 23;43(7):114464. doi: 10.1016/j.celrep.2024.114464. Epub 2024 Jul 8.
8
The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.F -box 结构域依赖的 EMI1 活性调节三阴性乳腺癌对 PARPi 的敏感性。
Mol Cell. 2019 Jan 17;73(2):224-237.e6. doi: 10.1016/j.molcel.2018.11.003. Epub 2018 Dec 13.
9
DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.DNA损伤修复与聚(ADP-核糖)聚合酶抑制在癌症治疗中的新作用
Clin Ther. 2016 Jul;38(7):1577-88. doi: 10.1016/j.clinthera.2016.06.006. Epub 2016 Jun 29.
10
ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2 Ovarian Cancer Cells.ALDH1A1 通过增强 BRCA2 卵巢癌细胞中的 DNA 修复来促进 PARP 抑制剂耐药性。
Mol Cancer Ther. 2020 Jan;19(1):199-210. doi: 10.1158/1535-7163.MCT-19-0242. Epub 2019 Sep 18.

引用本文的文献

1
Integrative Pan-Cancer Analysis Reveals the Oncogenic Role of MND1 and Validation of MND1's Role in Breast Cancer.综合泛癌分析揭示MND1的致癌作用及MND1在乳腺癌中作用的验证
J Inflamm Res. 2024 Jul 17;17:4721-4746. doi: 10.2147/JIR.S458832. eCollection 2024.
2
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.癌相关 FBXW7 缺失与 CDC7 的药物靶向治疗具有合成致死性。
Mol Oncol. 2024 Feb;18(2):369-385. doi: 10.1002/1878-0261.13537. Epub 2023 Oct 22.